These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 2101159)

  • 21. The 2-aminogluconate isomer of rhizobium sin-1 lipid A can antagonize TNF-alpha production induced by enteric LPS.
    Lee HS; Wolfert MA; Zhang Y; Boons GJ
    Chembiochem; 2006 Jan; 7(1):140-8. PubMed ID: 16317789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dissection of LPS-induced signaling pathways in murine macrophages using LPS analogs, LPS mimetics, and agents unrelated to LPS.
    Vogel SN; Manthey CL; Perera PY; Li ZY; Henricson BE
    Prog Clin Biol Res; 1995; 392():421-31. PubMed ID: 8524949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bacterial lipoprotein and lipopolysaccharide act synergistically to induce lethal shock and proinflammatory cytokine production.
    Zhang H; Peterson JW; Niesel DW; Klimpel GR
    J Immunol; 1997 Nov; 159(10):4868-78. PubMed ID: 9366412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monophosphoryl lipid A as a prophylactic for sepsis and septic shock.
    Gustafson GL; Rhodes MJ; Hegel T
    Prog Clin Biol Res; 1995; 392():567-79. PubMed ID: 8524964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced release of TNF and PCA from macrophages of tolerant mice.
    Haslberger A; Sayers T; Reiter H; Chung J; Schütze E
    Circ Shock; 1988 Oct; 26(2):185-92. PubMed ID: 3197264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A synthetic peptide derived from bactericidal/permeability-increasing protein neutralizes endotoxin in vitro and in vivo.
    Jiang Z; Hong Z; Guo W; Xiaoyun G; Gengfa L; Yongning L; Guangxia X
    Int Immunopharmacol; 2004 Apr; 4(4):527-37. PubMed ID: 15099530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The heat sensitivity of cytokine-inducing effect of lipopolysaccharide.
    Gao B; Wang Y; Tsan MF
    J Leukoc Biol; 2006 Aug; 80(2):359-66. PubMed ID: 16720829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bacterial lipopolysaccharides: structure, metabolism and mechanisms of action.
    Freudenberg MA; Galanos C
    Int Rev Immunol; 1990; 6(4):207-21. PubMed ID: 2102904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inverse relationship between the susceptibility of lipopolysaccharide (lipid A)-pretreated mice to the hypothermic and lethal effect of lipopolysaccharide.
    Greer GG; Rietschel ET
    Infect Immun; 1978 May; 20(2):366-74. PubMed ID: 669802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis of lipid A type carboxymethyl derivatives with ether chains instead of ester chains and their LPS-antagonistic activities.
    Watanabe Y; Miura K; Shiozaki M; Kanai S; Kurakata Si; Nishijima M
    Carbohydr Res; 2003 Jan; 338(1):47-54. PubMed ID: 12504380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor necrosis factor-inducing activities of lipid A preparations from Pseudomonas diminuta and Pseudomonas vesicularis.
    Arata S; Nakaya K; Furuhashi H; Nakamura Y; Hirayama T; Mashimo J; Kasai N
    Jpn J Cancer Res; 1988 May; 79(5):626-31. PubMed ID: 3136115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Practical stereoselective synthesis of alpha-linked C-glucosamine propionic acid esters: conversion to GLA-60 derivatives.
    Wakabayashi T; Shiozaki M; Kurakata S
    Carbohydr Res; 2002 Feb; 337(2):97-104. PubMed ID: 11814441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid A-induced responses in vivo.
    Sassi N; Paul C; Martin A; Bettaieb A; Jeannin JF
    Adv Exp Med Biol; 2010; 667():69-80. PubMed ID: 20665201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppression of antibody forming cells by lipid A analogs.
    Johnson AG; Odean MJ; Hasegawa A
    Adv Exp Med Biol; 1992; 319():63-7. PubMed ID: 1414606
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficient synthesis of novel monosaccharide analogs of lipids A.
    Nakamoto S; Takahashi T; Ikeda K; Achiwa K
    Chem Pharm Bull (Tokyo); 1985 Sep; 33(9):4098-101. PubMed ID: 4092305
    [No Abstract]   [Full Text] [Related]  

  • 36. Back to the future: is lipid A an appropriate target for the therapy of sepsis?
    Agnese DM; Lowry SF
    Crit Care Med; 2000 Aug; 28(8):3084-6. PubMed ID: 10966304
    [No Abstract]   [Full Text] [Related]  

  • 37. Engineering bacterial membrane nanovesicles for improved therapies in infectious diseases and cancer.
    Gao J; Su Y; Wang Z
    Adv Drug Deliv Rev; 2022 Jul; 186():114340. PubMed ID: 35569561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolerance-inducing mechanisms to lethal toxicity of LPS by synthetic lipid A analogs.
    Matsuura M; Ito Y; Kiso M; Hasegawa A; Homma JY
    Jpn J Med Sci Biol; 1990 Dec; 43(6):274-5. PubMed ID: 2101159
    [No Abstract]   [Full Text] [Related]  

  • 39. Natural and synthetic LPS and lipid a analogs or partial structures that antagonize or induce tolerance to LPS.
    Qureshi N; Jarvis B; Takayama K; Sattar N; Hofman J; Stütz P
    Prog Clin Biol Res; 1998; 397():289-300. PubMed ID: 9575570
    [No Abstract]   [Full Text] [Related]  

  • 40. Multistep regulation mechanisms for tolerance induction to lipopolysaccharide lethality in the tumor-necrosis-factor-alpha-mediated pathway. Application of non-toxic monosaccharide lipid A analogues for elucidation of mechanisms.
    Matsuura M; Kiso M; Hasegawa A; Nakano M
    Eur J Biochem; 1994 Apr; 221(1):335-41. PubMed ID: 8168521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.